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Abstract: Previously, it was suggested that the natural compound curcumin is an irreversible inhibitor
of rhodesain, the major lysosomal cysteine protease of the protozoan parasite Trypanosoma brucei.
The suggestion was based on a time-dependent inhibition of the enzyme by curcumin and a lack
of recovery of activity of the enzyme after pre-incubation with curcumin. This study provides
clear evidence that curcumin is a reversible, non-competitive inhibitor of rhodesain. In addition,
the study also shows that the apparent irreversible inhibition of curcumin is only observed when no
thiol-reducing reagent is included in the measuring buffer and insufficient solubilising agent is added
to fully dissolve curcumin in the aqueous solution. Thus, the previous observation that curcumin acts
as an irreversible inhibitor for rhodesain was based on a misinterpretation of experimental findings.
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1. Introduction
Curcumin is a natural phenol and has been extensively investigated as potential drug candidate
for various illnesses and medical conditions [1]. However, the compound has been classified as
a pan-assay interference compound (PAINS) and an invalid metabolic panacea (IMPS) [1]. PAINS are
compounds that show activity in different types of assay mainly through interfering with the assay
itself while IMPS are reagents that display activity against virtually any biological target. Despite this
and other drawbacks (chemical instability, low bioavailability, non-selectivity and toxicity), curcumin is
still subject of intense research and about 50 papers are published each week on biological interactions
of the compound [1].
Previously, it was shown that curcumin display anti-proliferative activity against the protozoan
parasite Trypanosoma brucei, the causative agent of sleeping sickness in humans and nagana disease
in livestock [2]. In search for the biological target involved in the trypanocidal activity of curcumin,
the effect of the compound on rhodesain, the major lysosomal cathepsin L cysteine protease in T. brucei,
has been recently investigated [3]. The enzyme is essential for the survival of the parasite and a valid
drug target [4]. It was shown that curcumin was able to inhibit rhodesain and it was suggested that
this inhibition was irreversible [3]. This conclusion was based on a weak non-linear relationship
between substrate hydrolysis and incubation time (with increasing incubation time the hydrolysis of
substrate decreased slightly) and the lack of recovery of enzyme activity after dilution of rhodesain
pre-incubated with curcumin [3,5]. However, it was also recently shown that the inhibition of rhodesain
by curcumin seemed to be reversible [6]. A 1:4 dilution of a reaction mixture containing rhodesain
and 10 µM curcumin resulted in a 4.7-fold increase in activity [6]. In order to prove conclusively that
curcumin is a reversible inhibitor, kinetic studies to determine the inhibitor type of the compound
were carried out. In addition, further investigations were conducted to provide explanations for the
apparent irreversible inactivation of rhodesain by curcumin recently observed [3,5]. The results of this
study revealed that curcumin is a reversible non-competitive inhibitor of rhodesain, a new finding that
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disproves unequivocally previous claims that curcumin is an irreversible inhibitor. This study also
showed that it is important to select the correct assay conditions to measure enzyme activity and to
consider the solubility properties of inhibitors otherwise incorrect data will be obtained leading to
a misinterpretation of results.
2. Results and Discussion
The activity of rhodesain was determined with the fluorogenic substrate benzyloxycarbonyl-
phenylalanyl-arginyl-7-amido-4-methyl coumarin (Z-FR-AMC), a substrate that is cleaved by
mammalian and trypanosome cathepsin L cysteine proteases [7,8].
Time course experiment revealed that the inhibition of rhodesain by curcumin was time
independent. In the presence of 6 µM curcumin (a concentration close to the IC50 value for the
inhibition of rhodesain by curcumin, see below), the inhibition of the activity of rhodesain was linear
with respect to time (Figure 1). The correlation coefficient of the readings was 0.9997 confirming
a strong linear association between substrate hydrolysis and incubation time. The same correlation
coefficient was also determined for the control reaction (Figure 1) indicating that there was no difference
in the linearity of the readings for the substrate hydrolysis in the presence and absence of curcumin.
In contrast, when rhodesain was incubated with the established irreversible cysteine protease inhibitor
CAA0255 [9] at 0.1 µM (a concentration below the IC50 value for the inhibition of rhodesain [4]),
the activity of the enzyme was quickly completely inhibited (Figure 1 insert). Within 5 min of incubation,
the activity of rhodesain was inhibited by >90%.
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Figure 1. Effect of curcumin and CAA0255 on the substrate hydrolysis activity of rhodesain. Purified
rhodesain (7 ng/mL; 0.2 nM) was incubated with 6 µM curcumin (squares), 0.1 µM CAA0255 (triangles),
or with DMSO alone (circles) in 100 mM citrate, pH 5.0, 2 mM dithiothreitol, 2% DMSO in the presence
of 5 µM of the fluorogenic substrate Z-FR-AMC. The release of free AMC was recorded every minute
for 30 min. r, correlation coefficient of the trend line. Insert, enlarged detail view of substrate hydrolysis
activity of rhodesain in the presence of curcumin and CAA0255 for the first 10 min. A representative
experiment out of three is shown.
After establishing that curcumin is a reversible inhibitor of rhodesain (see above and [6]),
kinetic studies to determine the inhibitor type of the compound were carried out. Double reciprocal
analysis (Lineweaver–Burk plot) gave a family of lines with increasing slopes as the curcumin
concentration increased (Figure 2a). The lines converged to the same point on the x-axis indicating
a non-competitive inhibition mechanism (Figure 2a). Plotting the reciprocal velocity (1/v) against
the inhibitor concentration (Dixon plot) gave again a family of lines that met in a single point on
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the x-axis confirming that curcumin is indeed a non-competitive inhibitor of rhodesain (Figure 2b).
From the point of intersection, the apparent inhibitor constant Ki for curcumin was determined to be
5.5 ± 1.4 µM (n = 3).
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Figure  3. Dose‐response  curve  of  the  inhibition  of  rhodesain  by  curcumin. Purified  rhodesain  (7 
ng/mL; 0.2 nM) was incubated with varying concentrations of curcumin (32, 16, 8, 4, 2 and 1 μM) in 















































Figure 2. Determination of inhibitor type and constant of curcumin for rhodesain. Purified rhodesain
(14 ng/mL = 0.4 nM) was incubated with varying concentrations of Z-FR-AMC (0.125, 0.167, 0.25 and
0.5 µM) and curcumin (0, 2, 4 and 6 µM) in 100 mM citrate, pH 5.0, 2 mM dithiothreitol, 2% DMSO.
(a) Lineweaver-Burk plot. The concentrations of curcumin were 0 µM (open circles), 2 µM (open
squares), 4 µM (open triangles) and 6 µM (open diamonds). (b) Dixon plot for determining the inhibitor
constant Ki. The concentrations of the substrate Z-FA-AMC were 0.5 µM (closed circles), 0.25 µM (closed
squares), 0.167 µM (closed triangles) and 0.125 µM (closed diamonds). A representative experiment
out of three is shown.
As for a non-competitive inhibitor, the Ki value is equal to the IC50 value [10]; the IC50 value of
curcumin for the inhibition of rhodesain was determined next. The compound inhibited the activity of
rhodesain in a dose-dependent manner with an IC50 value of 5.6 ± 0.5 µM (n = 3) (Figure 3). The IC50
value was not statistically significantly different from the Ki value (Student’s t test; p = 0.971). This
finding confirmed that curcumin is indeed a non-competitive inhibitor of rhodesain.
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Figure  3. Dose‐response  curve  of  the  inhibition  of  rhodesain  by  curcumin. Purified  rhodesain  (7 
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Figure 3. Dose-response curve of the inhibition of rhodesain by curcumin. Purified rhodesain (7 ng/mL;
0.2 nM) was incubated with arying concentrations of curcumin (32, 16, 8, 4, 2 and 1 µM) in 100 mM
citrate, pH 5.0, 2 mM dithiothreitol, 2% DMSO, 5 µM Z-FR-AMC. After 10 min, the fluorescence of
liberated AMC was measured. The experiment was repeated three times and mean values ± SD
are show .
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Having shown that curcumin is a reversible, non-competitive inhibitor of rhodesain, the question
remains why previously a lack of recovery of activity after pre-incubation of the resting enzyme
with the compound was found [3,5]. As the incubation of the active enzyme (i.e., in the presence of
substrate) with curcumin is reversible [6], one could conclude that the compound binds with different
affinities to the free enzyme and the enzyme-substrate complex. However, this explanation can be
excluded as a non-competitive inhibitor binds equally well to the enzyme whether or not it has
bound the substrate. A more likely reason for the observed apparent irreversible inhibitory activity of
curcumin is the very low water solubility of the compound, which is just 0.6 µg/mL (1.63 µM) [11].
In this context, it is important to note that in the recent studies rhodesain was pre-incubated with
50–100 µM curcumin for 30 min before the recovery of the activity of the enzyme was determined by
dilution of the reaction mixture into measuring buffer [3,5]. At concentrations of 50–100 µM, curcumin
will be rather dispersed than dissolved in aqueous solutions. This notion is supported by previous
observation that curcumin displays very low absorbance in aqueous solutions [12]. The dispersed
curcumin particles may absorb and/or non-specifically inactivate rhodesain present in the reaction
mixture. However, the water solubility of curcumin can be increased in the presence of DMSO
(Figure A1). In order to check whether undissolved curcumin can non-specifically inactivate rhodesain,
the enzyme was pre-incubated with 100 µM of the compound in the presence of DMSO at a low
concentration of 0.1% and at a high concentration of 10%, respectively. After 30 min incubation,
the reaction mixture was diluted 100-fold into measuring buffer containing substrate to give a curcumin
concentration of 1 µM that was shown not to affect the activity of rhodesain (see Figure 3). The activity
of rhodesain treated with curcumin in the presence of 0.1% DMSO was not fully restored after the
dilution (Figure 4). It reached only 30% of the control enzyme activity. In contrast, the activity of
rhodesain incubated with curcumin in the presence of 10% DMSO was restored to 91% of the control
enzyme activity after the dilution (Figure 4). In this case, the activity of the treated enzyme was
not statistically significantly different from that of the control enzyme (p = 0.337; Figure 4). This
result shows that curcumin, if it is dissolved with the help of an appropriate solubilising agent, does
not irreversibly inactivate rhodesain. Thus, the lack of recovery of curcumin pre-treated rhodesain
observed recently [3,5] seemed to be most likely due to non-specific inactivation by undissolved
curcumin particles present in the reaction mixture. Interestingly, a similar observation (lack of recovery
of enzyme activity after pre-incubation with curcumin) was previously reported for the inactivation of
CD13/aminopeptidase N [13]. While curcumin was identified as a reversible non-competitive inhibitor
of CD13/aminopeptidase N, the activity of the enzyme pre-treated with curcumin could not be fully
restored after three rounds of filtration using centrifugal filter devices to remove the compound.
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Figure 4. Reversibility of inhibition of rhodesain by curcumin. Purified rhodesain (3.4 µg/mL; 100 nM)
was pre-incubated in 100 mM citrate, pH 5.0, 2 mM dithiothreitol with 100 µM curcumin in the presence
of 0.1% or 10% DMSO. For controls, the enzyme was incubated under the same conditions but in
the absence of curcumin. After 30 min, the mixture was diluted 1:100 into 100 mM citrate, pH 5.0,
2 mM dithiothreitol, 2% DMSO, 5 µM Z-FR-AMC. After 10 min, the release of liberated AMC was
recorded. The specific activity (nmol AMC released/min/µg protein) was calculated using a standard
curve constructed with uncoupled AMC. Data are mean values ± SD of three experiments.
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Finally, the question remains as to why a time-dependent inhibition of rhodesain activity by
curcumin was recently observed [3,5]. In this regard, it should be mentioned that the measuring buffer
(assay buffer) used in the recent studies [3,5] did not contain any reducing thiol reagent. However,
cathepsin L cysteine proteases are only fully catalytically active in the presence of thiol reagents
(e.g., dithiothreitol, [14]). When determining the effect of curcumin on the activity of rhodesain in
measuring buffer lacking dithiothreitol, a time-dependent inactivation of the enzyme activity by the
compound was observed (Figure 5). After 30 min of incubation, the enzyme was almost completely
inactivated. However, after addition of dithiothreitol to a final concentration of 2 mM, rhodesain
regained its activity (Figure 5). Moreover, the activity of the enzyme was now linear with respect to
time with a correlation coefficient of the readings of 0.9997 (Figure 5). This result clearly demonstrates
that it is essential to include a thiol reagent in the measuring buffer in order to keep rhodesain fully
activated. It should also be pointed out that the activity of rhodesain decelerated when measured in the
absence of curcumin and dithiothreitol (Figure 5, insert). However, the time-dependent inactivation of
rhodesain in the absence of dithiothreitol for the curcumin-treated enzyme was more pronounced than
for the non-treated enzyme. These findings indicate that rhodesain in the absence of a thiol reagent is
oxidised, which leads to gradual inactivation of the enzyme. This oxidation of the rhodesain seems to
be accelerated in the presence of curcumin, which may be mistaken as an irreversible inhibition of
the enzyme.
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Figure 5. Effect of curcumin on substrate hydrolysis of rhodesain in the absence of the thiol dithiothreitol.
Purified rhodesain (35 ng/mL; 1 nM) was incubated with 6 µM curcumin (circles) in 100 mM citrate,
pH 5.0, 2% DMSO, in the presence of 5 µM of the fluorogenic substrate Z-FR-AMC. After 30 min,
dithiothreitol (DTT) was added to a final concentration of 2 mM (arrow). r, correlation coefficient of
the trend line. Insert, substrate hydrolysis of rhodesain in the absence of curcumin and dithiothreitol
(squares). The release of free AMC was recorded every minute for 30 and 60 min, respectively.
A representative experiment out of three is shown.
Other antioxidants (cysteine, glutathione, β-mercaptoethanol and ascorbic acid) were also able to
reactivate rhodesain that had been inhibited by curcumin, although at different effectiveness (Figure 6).
Cysteine was most effective in the reactivation of rhodesain (even better than dithiothreitol) while
ascorbic acid could not sustain the reactivation of the enzyme in the longer term. Glutathione was a slow
acting reagent but over time reactivated the enzyme to a similar extent asβ-mercaptoethanol. In general,
the effectiveness of the reactivation process of curcumin-inhibited rhodesain by the different antioxidants
(cysteine > dithiothreitol > glutathione = β-mercaptoethanol > ascorbic acid) was determined by their
standard redox potential E0’: the more negative E0’, the better the reactivation (E0’(cysteine) = −348 mV;
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E0’(dithiothreitol) = −323 mV; E0’(β-mercaptoethanol) = −207 mV; E0’(glutathione) = −205 mV;
E0’(ascorbic acid) = +58 mV [15–17]). These findings are further proof that the observed inhibition of
rhodesain by curcumin is due to oxidation of thiol groups in the enzyme.
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Figure 6. Effect of different antioxidants on the reactivation of rhodesain inhibited by curcumin.
Purified rhodesain (35 ng/mL; 1 nM) was incubated with 6 µM curcumin in 100 mM citrate, pH 5.0,
2% DMSO, in the presence of 5 µM of the fluorogenic substrate Z-FR-AMC. After 30 min, antioxidant
thiols were added to a final concentration of 4 mM (note that 4 mM of cysteine, glutathione and
β-mercaptoethanol (monothiols) equals to 2 mM dithiothreitol (dithiol) based on SH-groups present in
the reagents) while ascorbic acid was added to a final concentration of 20 mM (arrows). (a) cysteine;
(b) glutathione (note that the trend line was calculated using the readings from t = 40 min to t = 60 min);
(c) β-mercaptoethanol; (d) ascorbic acid (note that the trend line was calculated using the readings
from t = 31 min to t = 45 min). r, correlation coefficient of the trend line. The release of free AMC was
recorded every minute for 60 min. A representative experiment out of two or three is shown.
3. Materials and Methods
.1. Materials
Recombinantly expressed and purified rhodesain (T. brucei cathepsin L-like protease) was provide
by Professor Conor R. Caffrey, Center for Discovery and Innovation in Parasitic Diseases, Skaggs School
of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA.
Benzyloxycarbonyl-phenylalanyl-arginyl-7-amido-4-methyl coumarin (Z-FR-AMC) was purchased
from BIOMOL, Exeter, UK. Curcumin was bought from Sigma-Aldrich, Dorset, UK.
3.2. Enzyme Assays
The activity of rhodesain was determined with the fluorogenic substrate Z-FR-AMC in 100 mM
citrate, pH 5.0, 2 mM dithiothreitol (measuring buffer). Release of free 7-amino-4-methylcoumarin
(AMC) was measured at excitation and emission wavelengths of 360 nm and 460 nm in a BIORAD
VersaFluor fluorometer, Watford, UK.
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3.2.1. Time Course Assay
In order to determine whether the activity of rhodesain was inhibited in a time-dependent manner
by curcumin, the enzyme (7 ng/mL; 0.2 nM) was incubated in the presence of 6 µM curcumin dissolved
in DMSO in measuring buffer plus 5 µM Z-FR-AMC. For a negative control, rhodesain was incubated
with the same amount of DMSO (2%). For a positive control, the enzyme was incubated with 0.1 µM
of the established irreversible inhibitor CAA0255 [4,9].
To determine whether the absence of dithiothreitol had an effect on the inhibitory activity of
curcumin, rhodesain (35 ng/mL; 1 nM) was incubated with 6 µM curcumin in measuring buffer plus
5 µM Z-FR-AMC but lacking dithiothreitol. The release of free AMC was recorded every minute over
a period of 30 min. Then, different antioxidants (dithiothreitol, cysteine, glutathione,β-mercaptoethanol
and ascorbic acid) were added in order to determine whether curcumin-inhibited rhodesain could be
reactivated. The release of free AMC was recorded every minute for another period of 30 min.
3.2.2. Determination of Inhibitor Type and Ki
The inhibitor type of curcumin for rhodesain was determined by kinetic analysis. Purified
rhodesain was incubated with varying concentrations of Z-FR-AMC (0.125, 0.167, 0.25 and 0.5 µM)
and curcumin (0, 2, 4 and 6 µM) in measuring buffer containing 2% DMSO. The final concentration of
rhodesain in the assay was 14 ng/mL (0.4 nM). The release of free AMC was recorded as described
above every 30 s for 5 min. The velocity of the reaction (relative fluorescence units (RFU)/min) was
calculated by linear interpolation of the data. The inhibitor type and the Ki value were graphically
determined by Lineweaver–Burk plot and Dixon plot, respectively.
3.2.3. Determination of IC50
For determination of the half-maximal inhibitory concentration (IC50), purified rhodesain was
assayed with 5 µM Z-FR-AMC in measuring buffer containing different concentration of curcumin
(twofold dilutions from 32 µM to 1 µM) and 2% DMSO. Controls contained 2% DMSO alone.
The final enzyme concentrations in the assays were 7 ng/mL (0.2 nM). After 10 min incubation at
room temperature, the release of free AMC was recorded. IC50 values were determined by linear
interpolation according to the method by Huber and Koella [18].
3.2.4. Reversibility Assay
The effect of solvent on the reversibility of the inhibition of rhodesain by curcumin was tested
by measuring the recovery of enzymatic activity after dilution of the incubation mixture. Rhodesain
(3.5 µg/mL; 100 nM) was pre-incubated with 100 µM curcumin in the presence of 0.1% or 10% DMSO
in measuring buffer for 30 min at room temperature. Then, the mixture was diluted 100-fold into
measuring buffer containing 5 µM Z-FR-AMC. After 10 min incubation at room temperature, the release
of free AMC was recorded. Controls were pre-incubated under the same conditions but in the absence
of curcumin.
4. Conclusions
Through enzyme kinetic measurements, it was unequivocally shown that curcumin is a reversible,
non-competitive, inhibitor of rhodesain. Additional time course and dilution experiments provided
conclusive explanations as to why previously it was mistakenly suggested that curcumin is
an irreversible inhibitor of rhodesain. Taken together, this study has once more confirmed that
curcumin is a promiscuous molecule that can interact non-specifically with any protein under certain
incubation conditions leading to misinterpretation of results.
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Figure A1. Curcumin (100 nmol) was mixed in 1 mL of 100 mM citrate, pH 5.0 containing 0.1%, 1%
and 10% DMSO, respectively. Then, 200 µl of the solutions were pipetted into wells of a 96-well plate
and the absorbance read at 450 nm using a BioTek ELx808 microplate reader, Winooski, Vermont, USA.
Note that curcumin has an absorption maximum at around 430 nm in different polar solvents [12].
A blank (0.035) recorded with 200 µL of 100 mM citrate, pH 5.0 was subtracted from the absorbance
values. With increasing DMSO concentration, the absorbance of the solution also increased indicating
that more and more curcumin was being dissolved. In the presence of 10% DMSO, four and five times
more curcumin was dissolved than in the presence of 1% and 0.1% DMSO, respectively.
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